Background 

Down Syndrome, also known as trisomy 21, happens when a person is born with an extra copy of chromosome 21. People with Down Syndrome often have learning challenges, heart problems at birth, and a higher chance of developing certain childhood cancers like leukemia. Interestingly, even though they have higher rates of leukemia, adults with Down Syndrome are less likely to get some other cancers, including bladder cancer. Studies with animals have supported this idea, but researchers have not yet studied it closely in laboratory models to determine why this happens.   

What the Study Proposes to Address 

In an earlier study, scientists found that mice with Down Syndrome developed smaller and less advanced bladder tumors when cancer was caused by chemicals. They also discovered certain biological “pathways,” or processes, that influence how the cancer grows. When one of these pathways was blocked using a new drug called barasertib, bladder cancer did not develop in these mice. However, the current mouse model does not fully represent how the disease develops in humans. This study aims to test several Down Syndrome mouse models to confirm these findings and identify more possible drug targets. Researchers will develop bladder cancer in two different types of Down Syndrome mice using widely accepted mouse models to see if common pathways are altered.  Additionally, they will test whether barasertib truly prevents bladder cancer in these models which would validate them for use in identifying novel targets for therapy. 

Why This Research is Important 

If this study succeeds, it would show that studying Down Syndrome models can be used to reveal new and effective drug targets for treating bladder cancer. This research could lead to improved treatments for patients in the near future and open new paths for discovering therapies based on unique genetic differences that protect against cancer. 

None Reported as of August 2025

Department of Defense Peer Reviewed Cancer Research Program, “Targeting Dendritic Cells in Bladder Cancer Immunotherapy”, 2024, $653,928

Ben Woolbright, PhD; University of Kansas Medical Center
Katie Dennis, MD; University of Kansas Medical Center
Mihaela Sardiu, PhD; University of Kansas Medical Center